We are looking for a full-time, highly motivated individual to work as a bioinformatician in our team to develop prediction models using artificial intelligence for novel biotherapeutics development. More information If you are interested [...]
From Microviable in the International Day of Women and Girls in Science, we want to speakup for all the female working in STEM (Science, Technology, Engineering and Mathematics), not only for their great work but [...]
Microviable Therapeutics is looking for a full-time, highly motivated individual to work as a Quality Assurance CMO specialist with cGMP experience for novel biotherapeutic products. More information If you are interested in working with [...]
The European Medicines Agency (EMA) granted the qualification of “Small and Medium-Sized Enterprises” (SME) to Microviable Therapeutics. The European Medicines Agency (EMA) provides incentives and support for micro, small and medium-sized enterprises (SMEs) that are [...]
Checkout our new GutAlive® !! The unique user-friendly, high-capacity device for stool collection sampling and transport in anaerobic conditions that ensures sample stability, microbiota viability and preserves DNA integrity. GutAlive® preserves the [...]
Gijón, 21st July 2022, Microviable Therapeutics SL, a biotechnology company in preclinical stage developing novel microbiome-derived biotherapeutic products, announced a research agreement with the University Medical Center of Utrecht (The Netherlands) and Artizan Biosciences [...]
Gijón, July 7, 2022, Microviable Therapeutics SL, a biotechnology company in preclinical stage developing novel microbiome-derived biotherapeutic products, today announced that it has entered into a research contract with Venter Pharma SL. and Inmunomet [...]
It is always a pleasure to work with prestigious researchers. Congratulations Alejandro Lucia! for the award received. A group of ten researchers from various institutions, including Alejandro Lucia, a researcher at the European University and [...]
Microviable Therapeutics SL, a preclinical stage biotechnology company developing orally administered biological drugs based on microbiota-derived products, announced 1.5 million euros seed funding from the private medical group Inmunomet Intolerancia y Disbiosis SL. Microviable [...]
As part of our growth and consolidation as a microbiome company focused on therapeutics we have several openings to join our team! Are you ready to rock? Check out our careers section and submit [...]